The liver represents the first metastatic site in 5–12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45–103) and 15 months (95% CI 11–46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months versus 16 months; HR 0.083, p < 0.0001) and DFI (16 months versus 5 months; HR 0.17, p = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.

Orlandi, A., Pontolillo, L., Mele, C., Pasqualoni, M., Pannunzio, S., Cannizzaro, M. C., Cutigni, C., Palazzo, A., Garufi, G., Vellone, M., Ardito, F., Franceschini, G., Sanchez, A. M., Cassano, A., Giuliante, F., Bria, E., Tortora, G., Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis, <<JOURNAL OF PERSONALIZED MEDICINE>>, 2021; 11 (3): 187-187. [doi:10.3390/jpm11030187] [http://hdl.handle.net/10807/178068]

Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis

Orlandi A.;Pontolillo L.;Mele C.;Pasqualoni M.;Pannunzio S.;Cannizzaro M. C.;Cutigni C.;Garufi G.;Vellone M.;Ardito F.;Franceschini G.;Cassano A.;Giuliante F.;Bria E.;Tortora G.
2021

Abstract

The liver represents the first metastatic site in 5–12% of metastatic breast cancer (MBC) cases. In absence of reliable evidence, liver metastasectomy (LM) could represent a possible therapeutic option for selected MBC patients (patients) in clinical practice. A retrospective analysis including MBC patients who had undergone an LM after a multidisciplinary Tumor Board discussion at the Hepatobiliary Surgery Unit of Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS in Rome, between January 1994 and December 2019 was conducted. The primary endpoint was overall survival (OS) after a MBC-LM; the secondary endpoint was the disease-free interval (DFI) after surgery. Forty-nine MBC patients underwent LM, but clinical data were only available for 22 patients. After a median follow-up of 71 months, median OS and DFI were 67 months (95% CI 45–103) and 15 months (95% CI 11–46), respectively. At univariate analysis, the presence of a negative resection margin (R0) was the only factor that statistically significantly influenced OS (78 months versus 16 months; HR 0.083, p < 0.0001) and DFI (16 months versus 5 months; HR 0.17, p = 0.0058). A LM for MBC might represent a therapeutic option for selected patients. The radical nature of the surgical procedure performed in a high-flow center and after a multidisciplinary discussion appears essential for this therapeutic option.
Inglese
Orlandi, A., Pontolillo, L., Mele, C., Pasqualoni, M., Pannunzio, S., Cannizzaro, M. C., Cutigni, C., Palazzo, A., Garufi, G., Vellone, M., Ardito, F., Franceschini, G., Sanchez, A. M., Cassano, A., Giuliante, F., Bria, E., Tortora, G., Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis, <>, 2021; 11 (3): 187-187. [doi:10.3390/jpm11030187] [http://hdl.handle.net/10807/178068]
File in questo prodotto:
File Dimensione Formato  
orlandi_metastasi da mammella_jpm 2021.pdf

accesso aperto

Tipologia file ?: Postprint (versione finale dell’autore successiva alla peer-review)
Licenza: Creative commons
Dimensione 822 kB
Formato Adobe PDF
822 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/178068
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact